Effect of HPV Integration on Prognosis of Young Women With CIN2 in China

Inclusion Criteria:

• Female, 18 years of age or older and 45 years of age or younger, with a desire toconceive;

• Diagnosed with HSIL (CIN2) or HSIL (CIN2-3) via cervical tissue biopsy within thepast 3 months, and has not undergone cervical surgery, physical, or medicationtreatment;

• The lesion area under colposcopy is less than 50% of the total cervical area withinthe past 3 months;

• Plans for 12-month follow-up observation for CIN2, with no surgical, physical, ormedication treatment if the disease does not progress;

• Understands and voluntarily agrees to participate in the 12-month follow-up of thisstudy, and signs the informed consent form.

Exclusion Criteria:

• Cervical status at the time of enrollment as determined by colposcopy within thepast three months is Type III transformation zone;

• Pregnant or lactating;

• History of malignant reproductive tract tumors;

• History of hysterectomy, cervical surgery, or pelvic radiation therapy;

• Physical therapy to the cervix within 24 months prior to enrollment;

• The subject has a severe immune system disease that is active;

• Long-term use of contraceptives within 12 months prior to enrollment;

• Vaginal medication or irrigation within 72 hours prior to sampling (can re-enrollfor sampling 3 days after cessation);

• Sexual intercourse within 24 hours prior to sampling (can re-enroll for sampling 24hours after cessation);

• Received treatment for genital tract infections, HPV, or other STD pathogens withinthe past month (can re-enroll one month after cessation of treatment);

• Used antibiotics or vaginal microecological improvement products within the pastmonth (can re-enroll one month after cessation of use);